NOD2 and colitis: Collectively, these in vitro and in vivo studies strongly suggest that MDP activation of NOD2 inhibits TLR9-induced type I IFN responses through the removal of the K63-linked polyubiquitination of TRAF3 by OTUD5 activation, and thereby suppresses the development of TLR9-induced colitis.